Scarica l'app Stockscreener
7.38
6.11%
-0.48
Dopo l'orario di chiusura:
7.50
0.12
+1.63%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché TNXP Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.86
Aprire:
$7.79
Volume 24 ore:
229.83K
Relative Volume:
0.16
Capitalizzazione di mercato:
$44.24M
Reddito:
-
Utile/perdita netta:
$-121.02M
Rapporto P/E:
-0.6554
EPS:
-11.26
Flusso di cassa netto:
$-114.09M
1 W Prestazione:
-15.85%
1M Prestazione:
-62.13%
6M Prestazione:
-56.05%
1 anno Prestazione:
-99.38%
Intervallo 1D:
$7.31
$7.9786
Intervallo di 1 settimana:
$7.31
$9.139
Portata 52W:
$7.31
$1,221.76
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Nome
Tonix Pharmaceuticals Holding Corp
Settore
Industria
Telefono
212-980-9155
Indirizzo
26 MAIN STREET, SUITE 101, CHATHAM, NY
Confronta TNXP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
7.38 | 44.24M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-04-18 | Iniziato | Noble Capital Markets | Outperform |
| 2019-04-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Downgrade | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Reiterato | Oppenheimer | Outperform |
| 2015-11-04 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-06-12 | Iniziato | Oppenheimer | Outperform |
| 2015-02-17 | Reiterato | ROTH Capital | Buy |
| 2014-09-29 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Tonix Pharmaceuticals Holding Corp Borsa (TNXP) Ultime notizie
Global Artificial Intelligence in Drug Commercialization Market to Observe Stupendous Growth at a CAGR of ~24% by 2032 | DelveInsight - GlobeNewswire Inc.
Tonix Pharm stock plunges to 52-week low of $7.84 By Investing.com - Investing.com Australia
Tonix Pharm stock plunges to 52-week low of $7.84 - Investing.com
Tonix reports positive results in TNX-1500 phase 1 trial - MSN
TNXP: PDUFA Date for TNX-102 SL in Fibromyalgia of August 15, 2025 - Smartkarma
TNXP: PDUFA Date for TNX-102 SL in Fibromyalgia of August 15, 2025… - Yahoo Finance
(TNXP) Investment Analysis - Stock Traders Daily
(TNXP) On The My Stocks Page - Stock Traders Daily
Tonix Pharmaceuticals appoints new CTO amid drug development - MSN
Tonix Pharmaceuticals reports positive phase 1 results for TNX-1500, advancing to Phase 2 - Proactive Investors USA
Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights - ADVFN
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap DownHere's Why - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap UpWhat's Next? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 13.2%Should You Buy? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 12.6%Time to Sell? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 3.7%Should You Sell? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 3.7%What's Next? - MarketBeat
Tonix Pharma says it had about $98.8M in cash and cash equivalents as of Dec 31, 2024 - MSN
Tonix Pharmaceuticals Rises After Preliminary 2024 Results -February 07, 2025 at 03:39 pm EST - Marketscreener.com
Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash - GlobeNewswire
Tonix stock gains on business update, preliminary earnings report - Seeking Alpha
What's Going On With Tonix Pharmaceuticals Shares Friday? - Benzinga
Tonix Pharmaceuticals reports positive topline trial outcomes of TNX-1500 - Clinical Trials Arena
TNXP Financial Results: Strong Sales Growth & Strategic Cash Position Ahead of Critical FDA Date - StockTitan
Tonix Pharma Announces Promising Phase 1 Trial Results - TipRanks
Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases - GlobeNewswire
Breakthrough in Transplant Medicine: Novel Anti-CD40L Antibody Achieves Key Clinical Milestones - StockTitan
Tonix Pharmaceuticals announces reverse stock split - MSN
Tonix Pharmaceuticals (NASDAQ:TNXP) Coverage Initiated by Analysts at StockNews.com - MarketBeat
TNXPTonix Pharmaceuticals Holding Corp. Latest Stock News & Market Updates - StockTitan
Tonix Pharmaceuticals to Present at BIO CEO & Investor Conference on February 10, 2025 - Nasdaq
Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference - GlobeNewswire
Tonix's FDA Fast-Tracked Fibromyalgia Treatment Takes Center Stage at Major Investor Conference - StockTitan
Tonix Pharmaceuticals appoints new CTO amid drug development By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals promotes Fogarty to CTO - MSN
Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer - citybiz
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 7.7%Should You Sell? - MarketBeat
Tonix Pharma Promotes Fogarty to Chief Technology Officer - TipRanks
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Craters on Stock Split before FDA Call - TipRanks
Tonix's Leadership Shakeup: New CTO to Spearhead $34M Defense Contract & Critical FDA Review - StockTitan
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 11.5% HigherWhat's Next? - MarketBeat
Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - Benzinga
Tonix Pharmaceuticals Holding Corp Azioni (TNXP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
6.45%
1.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):